Business Context and Reporting Period
Company: Cryolife, Inc. (Note: Metadata listed "Artivion, Inc." but filing text confirms registrant is Cryolife, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1996
Business Overview: Cryolife provides cryopreservation services for human heart valves, saphenous veins, and orthopaedic tissues, as well as porcine valves. The company operates in a seasonal industry with peak demand in the second and third quarters.
Key Financial Metrics
| Metric | 3 Months Ended Sep 30, 1996 | 9 Months Ended Sep 30, 1996 | 9 Months Ended Sep 30, 1995 |
|---|---|---|---|
| Total Revenues | $10,410,624 | $28,542,326 | $22,181,885 |
| Net Income | $1,261,429 | $3,032,390 | $1,634,834 |
| Earnings Per Share | $0.13 | $0.31 | $0.17 |
| Net Cash from Operations | N/A | $2,244,772 | $2,500,499 |
| Net Cash Used in Investing | N/A | ($5,613,669) | ($4,251,147) |
| Cash & Equivalents (End Period) | $97,145 | $97,145 | $1,094,521 |
| Working Capital | $12.9 million | $12.9 million | $15.1 million (Dec 31, 1995) |
| Current Ratio | 3.8 to 1 | 3.8 to 1 | N/A |
Debt & Liquidity: The company executed a $10 million revolving term loan agreement on August 30, 1996. Total liabilities increased to $8.1 million from $3.1 million at year-end 1995, driven by long-term liabilities related to acquisitions and credit facility draws.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 25% for the quarter and 29% for the nine-month period compared to 1995. This was driven by a 31% increase in tissue shipments.
- Product Mix Shifts:
- Human Heart Valves: Revenue increased 25% (quarter) and 26% (nine months), accounting for 68% of total revenue.
- Orthopaedic Tissue: Revenue surged 133% (quarter) and 147% (nine months) due to a 218% increase in shipments.
- Vein Preservation: Revenue increased 22% (quarter) and 20% (nine months).
- Other Revenue: Decreased due to lower interest income from reduced investments.
- Expense Trends:
- Preservation Costs: Increased 13% (quarter) and 18% (nine months) due to higher shipment volumes, though as a percentage of revenue, costs improved slightly (35% vs 38% in prior year).
- G&A Expenses: Increased 22% (quarter) and 27% (nine months), reflecting a strategic shift from an independent sales force to a direct sales force.
- Capital Expenditures: Significant increase in investing cash outflows ($7.1 million for nine months) primarily due to the construction of a new corporate headquarters.
Guidance, Outlook, and Risks
- Acquisitions: On September 12, 1996, the company acquired assets of United Cryopreservation Foundation, Inc. (UCFI) for $2 million payable over five years. The impact on Q3 operations was not significant.
- Liquidity Outlook: Management believes cash, marketable securities, operating cash flow, and the new $10 million credit facility are sufficient for foreseeable needs.
- Seasonality: Demand for human heart valves is seasonal, peaking in Q2 and Q3 due to pediatric surgery schedules.
- Risks: Forward-looking statements are subject to risks including government regulation, competitive position, tissue availability, product development status, intellectual property protection, and third-party reimbursement rates.
Investor Verification Checklist
- Acquisition Integration: Verify the long-term financial impact and integration costs of the UCFI acquisition.
- Capital Expenditure Completion: Confirm the final cost and timeline for the new corporate headquarters construction.
- Debt Covenants: Review the restrictive covenants in the new $10 million credit facility, specifically regarding financial ratios and tangible net worth.
- Seasonal Demand: Monitor Q4 and Q1 revenue trends to assess the severity of the seasonal downturn.
- Reimbursement Rates: Track changes in third-party payer reimbursement policies which could affect future margins.